InsidersTradesSigma
Track the GALECTIN THERAPEUTICS INCORPORATED share price and the full insider trade history of the company, a publicly traded company based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Market capitalisation: €267.4m. The latest transaction was filed on 29 June 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Harold Shlevin. The full history is free.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
2 of 2 declarations
GALECTIN THERAPEUTICS INCORPORATED is a biotechnology company focused on developing treatments for serious diseases by targeting galectins, proteins involved in various pathological processes.